Advertisement
Document › Details
PentixaPharm GmbH. (2/6/20). "Press Release: PentixaPharm Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics". Würzburg.
Organisation | PentixaPharm GmbH | |
Today | Pentixapharm AG, Berlin | |
Group | Pentixapharm (Group) | |
Organisation 2 | 1717 Life Science Ventures GmbH | |
Product | theranostics (Tx) | |
Product 2 | venture capital | |
Index term | PentixaPharm–SEVERAL: investment, 202002 financing round Series A €15m led by ELSA Eckert Life Science Accelerator | |
Funding will be used for phase I / phase II trials of the lead program PentixaTher/ PentixaFor
PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
Interviews:
“With the renowned expertise of the PentixaPharm team, the company is well positioned to bring the lead-compounds PentixaFor and PentixaTher with an effective clinical development program to the next level. We are thrilled to accompany this venture.”, says Phillip Eckert, Responsible Programme Manager and Partner at ELSA.
“Scintomics is very excited about this new partnership marking another important milestone towards a strong positioning of PentixaPharm as radiopharmaceutical development specialist”, comments Saskia Kropf, CEO of Scintomics. Prof. Hans-Jürgen Wester, founder of Scintomics, adds: “We are enthusiastic by this round A financing to advance the CXCR4 program. Preclinical and clinical data so far have demonstrated encouraging evidence and good potential for targeted cancer therapies. Now with the experienced development team of PentixaPharm, we are sure to quickly establish this theranostic approach towards meaningful clinical trials.”
“We are delighted that in ELSA we have found a strong financing partner with an outstanding expertise in the radiopharmaceutical field. The proceeds of the series A financing will enable us to bring a new treatment for CNS Lymphoma, up to today a disease with limited treatment options, a little closer to patients in need”, adds Anna Steeger, Co-founder of 1717 LSV GmbH and CEO of PentixaPharm.
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with a- or ß-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About ELSA Eckert Life Science Accelerator
ELSA, a subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies, which are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature companies.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalised cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
Contacts
Dr. Hakim Bouterfa, CEO PentixaPharm
+49 931 304998330
hakim.bouterfa@1717lsv.com
Record changed: 2023-06-05 |
Advertisement
More documents for Pentixapharm (Group)
- [1] |transkript [Kääb, Georg]. (9/24/24). "First German Life Sciences IPO since 2016 – Radiopharma Company Pentixapharm Lists at Frankfurt Stock Exchange. Interview by |transkript.de/Georg Kääb with Andreas Eckert"....
- [2] Pentixapharm Holding AG. (9/23/24). "Press Release: Pentixapharm Holding AG Sets Price Range for Planned IPO [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg....
- [3] Pentixapharm Holding AG. (9/12/24). "Press Release: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg....
- [4] Pentixapharm Holding AG. (8/26/24). "Press Release: Pentixapharm AG Receives Orphan Drug Designation for its Radiodiagnostic Tracer PentixaFor in Marginal Zone Lymphoma by the European Medicines Agency". Berlin & Würzburg....
- [5] Pentixapharm AG. (7/3/24). "Press Release: Pentixapharm Acquires Target Discovery Business of Glycotope". Würzburg & Berlin....
- [6] Eckert & Ziegler Strahlen- und Medizintechnik AG. (6/8/23). "Press Release: PentixaPharm Receives BfArM-Clearance for Its Therapeutic to Conduct a Clinical Trial in Lymphoma". Würzburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top